COEPTIS announced it has successfully licensed exclusive worldwide development and commercialization rights to the GEAR Cell Therapy Platform, representing a first-in-class approach to modifying potent cancer-targeting immune cells to optimize the likelihood of deep remission in patients with hematologic malignancies and other cancers. Coeptis had previously held limited co-development rights to GEAR. As part of this exclusive GEAR license agreement with VyGen-Bio, Inc., Coeptis has formed a new majority-owned subsidiary, GEAR Therapeutics, Inc., with the mission to advance GEAR-based cell therapy towards human proof-of-concept studies to initially evaluate GEAR-modified natural killer cells for the treatment of a broad range of cancers and other therapeutic modalities.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COEP:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue